Irbesartan Eg (Irbesartan)

Irbesartan belongs to the ARB class and is employed in conditions where the renin‑angiotensin system contributes to disease progression.

• Hypertension: lowers elevated blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows the decline of renal function in patients with type 2 diabetes.
• Proteinuric kidney disease: decreases urinary protein excretion and helps preserve kidney health.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal tissue. By preventing angiotensin II binding, it inhibits vasoconstriction, aldosterone release, and sympathetic activation, leading to reduced peripheral resistance, lower blood pressure, and decreased renal pressure load.

Irbesartan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Hyperkalemia: elevated potassium levels detectable on blood tests.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Angioedema: rapid swelling of the face, lips, tongue, or throat.
• Acute renal failure: sudden loss of kidney function.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Severe hypotension: dangerously low blood pressure causing fainting.
• Neutropenia: marked reduction in white blood cells.
• Anaphylactic reaction: life‑threatening allergic response.

Before initiating Irbesartan therapy, several safety considerations should be observed.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Assess renal function: check serum creatinine and eGFR regularly.
• Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents.
• Use caution in hepatic impairment: dose adjustments may be required.
• Contraindicated in pregnancy: avoid exposure due to fetal risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use may increase renal risk.
• Dual blockade with ACE inhibitors or other ARBs: heightened risk of hypotension and renal impairment.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.
• Lithium: concurrent use can raise lithium concentrations.
• NSAIDs (high‑dose): can reduce renal perfusion and blunt antihypertensive effect.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure lowering.
• CYP3A4 inhibitors (e.g., azole antifungals): can increase Irbesartan plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce drug exposure.
• Other antihypertensives: additive hypotensive effect requires dose titration.